Phytochemical Screening and Bioactivities of Cactaceae Family Members Endemic to Mexico.

Mexico is a center of diversification for the Cactaceae family, with 69% of the species recorded as endemic. Certain members of the Cactaceae family have been chemically analyzed to relate their medicinal use with their phytochemistry. Here, the phytochemistry and bioactivity of ethanol extracts of Ferocactus echidne, F. latispinus, and Mammillaria geminispina were evaluated. A preliminary phytochemical analysis was performed, detecting the presence of saponins, tannins, cardiotonic glycosides, and sesquiterpene lactones. The presence of nicotinic acid in F. echidne and F. latispinus was identified by GC-MS. Other compounds found in the extracts of these three species were gentisic acid, diosmetin, chlorogenic acid, N-methyltyramide, and hordenine. The antioxidant activity was estimated with the DPPH free radical scavenging test. To determine the toxicity of the extracts, the in vivo model of Artemia spp. was used. In addition, the cytotoxicity of the extract was tested on C6, HaCaT, THP-1, and U937 cell lines, while the inflammatory activity was tested by measuring the secretion of cytokines using macrophage cells. The three species showed different bioactivities, including antioxidant, antimicrobial, cytotoxic, and anti-inflammatory activities. To the best of our knowledge, the results presented here are the first described for these species.

Antimycobacterial, cytotoxic, and anti-inflammatory activities of Artemisialudoviciana.

ETHNOPHARMACOLOGICAL RELEVANCE: A third part of the world population has been exposed to the pathogen Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB). TB is a deadly disease, and its treatment has been hampered because of the lack of new antibiotics or the development of new antimycobacterial agents against this pathogen. The situation is aggravated because of the appearance of multidrug-resistant strains. In Mexican traditional medicine, records showed Artemisia ludoviciana for the treatment of TB. Thus, the combination of antibiotics and plant extracts might represent new antimycobacterial agents as an attractive alternative. MATERIALS AND METHODS: The biological activities of ethanol extract obtained from A. ludoviciana were evaluated for its antimycobacterial activities using an M. tuberculosis clinical isolate. Also, the toxicity of the extracts was assessed ex vivo and in vivo using the human-derived macrophages cell line (THP-1) and the Artemia spp. model, respectively. Lastly, the inflammatory response of macrophages exposed to the extracts was also evaluated. RESULTS: The ethanol extract of A. ludoviciana showed antimycobacterial activity with a MIC of 250 µg/mL against a clinical strain of M. tuberculosis. Ex vivo cytotoxicity using the THP-1 cell line incubated with the ethanol extract showed an IC50 of 20 µg/mL. On the other hand, the Artemia model's toxicity test showed moderate toxicity when the A. ludoviciana extract was tested with LC50 of 195.64 µg/mL. Analysis of the inflammatory response of THP-1 cells exposed to the same extract showed no increase in secreted interleukine-6 and -10. Also, no effect was observed in the pro-inflammatory tumor necrosis factor-α cytokine level. Moreover, a chemical profile of the extracts identified achillin as the major component in the ethanol extract, along with other minor components such as thujone and stigmasterol. CONCLUSIONS: We showed that the ethanol extract of A. ludoviciana possessed antimycobacterial activity and could potentially be used to supplement the antibiotic treatment of TB.

Immunological and technical considerations in application of alginate-based microencapsulation systems.

Islets encapsulated in immunoprotective microcapsules are being proposed as an alternative for insulin therapy for treatment of type 1 diabetes. Many materials for producing microcapsules have been proposed but only alginate does currently qualify as ready for clinical application. However, many different alginate-based capsule systems do exist. A pitfall in the field is that these systems are applied without a targeted strategy with varying degrees of success as a consequence. In the current review, the different properties of alginate-based systems are reviewed in view of future application in humans. The use of allogeneic and xenogeneic islet sources are discussed with acknowledging the different degrees of immune protection the encapsulation system should supply. Also issues such as oxygen supply and the role of danger associated molecular patterns (DAMPS) in immune activation are being reviewed. A common property of the encapsulation systems is that alginates for medical application should have an extreme high degree of purity and lack pathogen-associated molecular patterns (PAMPs) to avoid activation of the recipient's immune system. Up to now, non-inflammatory alginates are only produced on a lab-scale and are not yet commercially available. This is a major pitfall on the route to human application. Also the lack of predictive pre-clinical models is a burden. The principle differences between relevant innate and adaptive immune responses in humans and other species are reviewed. Especially, the extreme differences between the immune system of non-human primates and humans are cumbersome as non-human primates may not be predictive of the immune responses in humans, as opposed to the popular belief of regulatory agencies. Current insight is that although the technology is versatile major research efforts are required for identifying the mechanical, immunological, and physico-chemical requirements that alginate-based capsules should meet for successful human application.